UPA TIDLIRA 30 Tirzepatide Compound Peptide Pen 30mg - 3ml

Weight Management • Appetite Control • Metabolic Support

TIDLIRA™ is a next-generation injectable treatment powered by Tirzepatide, a breakthrough dual receptor agonist. By simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, TIDLIRA™ offers a comprehensive metabolic solution. This dual-action mechanism regulates blood sugar, controls appetite, and promotes significant, sustainable weight loss.

Key Benefits

• Glycemic Control: Supports healthy, stable blood sugar levels.
• Satiety Support: Reduces hunger and promotes a feeling of fullness.
• Sustained Weight Loss: Encourages steady, long-term weight reduction.
• Convenience: Once-weekly self-injection designed to fit your lifestyle.
• Clinical Grade: Pharmaceutical-grade formulation with proven efficacy.

Disclaimer

This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPRA) for human or animal use.

Not for human consumption or medical use. Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, the customer confirms they are qualified to handle and use this product in accordance with applicable laws and regulations.